Automated Large-Scale Production of Paclitaxel Loaded Mesenchymal Stromal Cells for Cell Therapy Applications
Open Access
- 29 April 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (5), 411
- https://doi.org/10.3390/pharmaceutics12050411
Abstract
Mesenchymal stromal cells (MSCs) prepared as advanced therapies medicinal products (ATMPs) have been widely used for the treatment of different diseases. The latest developments concern the possibility to use MSCs as carrier of molecules, including chemotherapeutic drugs. Taking advantage of their intrinsic homing feature, MSCs may improve drugs localization in the disease area. However, for cell therapy applications, a significant number of MSCs loaded with the drug is required. We here investigate the possibility to produce a large amount of Good Manufacturing Practice (GMP)-compliant MSCs loaded with the chemotherapeutic drug Paclitaxel (MSCs-PTX), using a closed bioreactor system. Cells were obtained starting from 13 adipose tissue lipoaspirates. All samples were characterized in terms of number/viability, morphology, growth kinetics, and immunophenotype. The ability of MSCs to internalize PTX as well as the antiproliferative activity of the MSCs-PTX in vitro was also assessed. The results demonstrate that our approach allows a large scale expansion of cells within a week; the MSCs-PTX, despite a different morphology from MSCs, displayed the typical features of MSCs in terms of viability, adhesion capacity, and phenotype. In addition, MSCs showed the ability to internalize PTX and finally to kill cancer cells, inhibiting the proliferation of tumor lines in vitro. In summary our results demonstrate for the first time that it is possible to obtain, in a short time, large amounts of MSCs loaded with PTX to be used in clinical trials for the treatment of patients with oncological diseases.This publication has 40 references indexed in Scilit:
- Tissue-derived mesenchymal stromal cells used as vehicles for anti-tumor therapy exert different in vivoeffects on migration capacity and tumor growthBMC Medicine, 2013
- Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia‐bearing miceBritish Journal of Haematology, 2013
- Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell TherapyTransplantation and Cellular Therapy, 2012
- Mesenchymal Stromal Cells Primed with Paclitaxel Provide a New Approach for Cancer TherapyPLOS ONE, 2011
- TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell populationBritish Journal of Cancer, 2010
- Mesenchymal stem cells in health and diseaseNature Reviews Immunology, 2008
- NCI-navy medical oncology branch cell line data baseJournal of Cellular Biochemistry, 1996
- Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6?-hydroxytaxolCancer Chemotherapy and Pharmacology, 1995
- Pancreatic adenocarcinoma in a patient with cystic fibrosisThe American Journal of Medicine, 1988
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983